Want to see PHAR full AI Analyst Report?
PHAR Stock Chart & Stats
$11.77
-$0.55(-4.21%)
At close: 4:00 PM EDT
$11.77
-$0.55(-4.21%)
Day’s Range― - ―
52-Week Range$9.62 - $21.34
Previous Close$12.62
Volume5.37K
Average Volume (3M)22.76K
Market Cap
$745.12M
Enterprise Value$1.08K
Total Cash (Recent Filing)$158.28M
Total Debt (Recent Filing)$113.30M
Price to Earnings (P/E)71.6
Beta0.39
Next Earnings
Nov 05, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding70,778,120
10 Day Avg. Volume19,428
30 Day Avg. Volume22,759
Financial Highlights & Ratios
PEG Ratio-3.60
Price to Book (P/B)4.55
Price to Sales (P/S)3.35
P/FCF Ratio23.36
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$37.50Price Target Upside218.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.23
Revenue Forecast (FY)$390.63M
Bulls Say, Bears Say
Bulls Say
Joenja Growth And ExpansionJoenja is demonstrating strong commercial momentum through higher revenue, patient growth, international launches, and potential pediatric expansion. This broadens Pharming’s recurring rare-disease revenue base and provides a durable growth engine that can increasingly offset pressure on the established RUCONEST franchise.
Strong Gross ProfitabilityThe very high gross margin indicates that Pharming’s approved therapies retain substantial economic value after product costs. If broadly maintained, this margin structure can support investment in research, commercialization, and new indications while providing operating leverage as revenue scales.
Manageable LeverageModerate leverage gives Pharming more financial flexibility than a highly indebted biotechnology company. The improved debt-to-equity position reduces balance-sheet strain and supports continued funding of the development pipeline, although current returns on equity remain modest.
Bears Say
Revenue And RUCONEST PressureLowered guidance and declining RUCONEST revenue show that Pharming’s growth outlook remains dependent on successful Joenja expansion. Competitive pressure and the mature product’s weakness can constrain consolidated revenue, making the transition to a broader portfolio more important.
Volatile Cash GenerationPositive current cash generation is not yet consistent across periods, and recent operating outflows demonstrate sensitivity to business or working-capital swings. Continued volatility could limit internally funded investment and make execution of the pipeline more dependent on maintaining commercial performance.
Thin Profitability Under R&D InvestmentA thin bottom-line margin leaves limited buffer for higher research spending or weaker product revenue. Although the investment may support future indications, the near-term combination of rising R&D costs and lower adjusted operating profit can suppress earnings and cash conversion.
Pharming Group News
PHAR FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was $9.62 and its highest was $21.34 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is $745.12M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Nov 05, 2026 which is in 45 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Jul 30, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.063 by -$0.043.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Undervalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is 0.11.
How many shares outstanding does Pharming Group have?
Pharming Group has 70,778,120 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of $0.02 in its last earnings report, missing expectations of $0.063. Following the earnings report the stock price went down -10.491%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in PHAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharming Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.50 (218.61% Upside)
$37.50 (218.61% Upside)
Blogger Sentiment
Bullish
PHAR Sentiment 100%
Sector Average 63%
Sector Average 63%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharming Group
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
PHAR Company Deck
PHAR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum for Joenja (robust percentage growth, geographic and pediatric expansion) and encouraging underlying RUCONEST demand indicators (active patient base ~93%, sequential revenue rebound) are offset by near-term headwinds — RUCONEST year-over-year revenue declines, a $30M revenue guidance reduction, operating cash outflows, and a manufacturing inventory impairment. Management emphasized cost discipline, positive operating profit in Q2, sufficient cash to fund the pipeline, and several upcoming clinical catalysts (leniolisib Phase II readouts in Q4, napazimone in 2027) that could materially change the trajectory. Given the balance of meaningful near-term challenges against several concrete growth drivers and pipeline milestones, the overall tone is cautious and balanced.View all PHAR earnings summariesPHAR Stock 12 Month Forecast
Average Price Target
$37.50
▲(218.61% Upside)
Technical Analysis
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.13% Other Institutional Investors
96.85% Public Companies and
Individual Investors